SciELO - Scientific Electronic Library Online

SciELO - Scientific Electronic Library Online

Referencias del artículo

SEMENIUK, Guillermo. Células madre: Vida más allá de la muerte. Medicina (B. Aires) [online]. 2012, vol.72, n.5, pp. 443-444. ISSN 0025-7680.

    1. Latil M, Rocheteau P, Châtre L, et al. Skeletal muscle stem cells adopt a dormant cell state postmortem and retain regenerative capacity. Nat Commun 2012; Jun 12; 3: 903. En: http://www.nature.com/ncomms/journal/v3/n6/pdf/ncomms1890.pdf; consultado 3/8/12; Press release, I. Pasteur. En: http://www.pasteur.fr/ip/easysite/pasteur/en/press/press-releases/2012/postmortem-stem-cells; consultado 20/8/12. [ Links ]

    2. Vogel G. Cancer Stem Cells Can Fuel Tumor Growth. En: http://www.wired.com/wiredscience/2012/08/cancer-stemcells/; consultado 3/8/12. [ Links ]

    3. Schepers A G, Snippert H J, Stange D E, et al. Lineage Tracing Reveal Lgr5+ Stem Cell Activity in Mouse Intestinal Adenoma. Science, 2012; 337: 730-5. [ Links ]

    4. Zhenyu Tang, Aijun Wang, Falei Yuan, et al. Differentiation of multipotent vascular stem cells contributes to vascular diseases. Nature Communications, June 2012. En: http://www.nature.com/ncomms/journal/v3/n6/full/ncomms1867.html; consultado 3/8/12. [ Links ]

    5. Semeniuk GB. Stem cells en relación a la reparación de lesiones pulmonares. Revista Argentina de Medicina Respiratoria 2005; 1: 1-2. [ Links ]

    6. Pasqualini CD. Reprogramación de fibroblastos humanos a células madre. Nuevo paradigma en medicina regenerativa. Medicina (B Aires) 2008; 68: 181-3. [ Links ]

    7. Pasqualini CD. La guerra contra el cáncer. Medicina (B Aires) 2011; 71: 496-9. [ Links ]

    1. Allison, RS. Disseminated sclerosis in North Wales: an inquiry into its incidence, frequency, distribution and other etiological factors. Brain 1931; 53: 391-430. [ Links ]

    2. Poser, CM. An Atlas of Multiple Sclerosis; In: Multiple sclerosis: epidemiology. 2nd ed. Nashville: Parthenon Publishing Group 1998, p 23-35. [ Links ]

    3. Pugliatti M, Sotgiu S, Rosati G. The worldwide prevalence of multiple sclerosis. Clin Neurol Neurosurg 2002; 104: 182-91. [ Links ]

    4. Rosati G. The prevalence of multiple sclerosis in the world: an update. Neurol Sci 2001; 22: 117-39. [ Links ]

    5. Rosati G, Aiello I, Pirastru MI, et al. Epidemiology of multiple sclerosis in Northwestern Sardinia: further evidence for higher frequency in Sardinians compared to other Italians. Neuroepidemiology 1996; 15: 10-9. [ Links ]

    6. Cristiano E, Patrucco L, Rojas JI. A systematic review of the epidemiology of multiple sclerosis in South America. Eur J Neurol 2008; 15: 1273-8. [ Links ]

    7. Rosati G. Descriptive epidemiology of multiple sclerosis in Europe in the 1980s: a critical overview. Ann Neurol 1994; 36 Suppl 2: S164-74. [ Links ]

    8. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-12. [ Links ]

    9. Moher D, Liberati A, Tetzlaff J, Altman D. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097. [ Links ]

    10. Cristiano E, Patrucco L, Rojas JI, et al. Prevalence of multiple sclerosis in Buenos Aires, Argentina using the capture-recapture method. Eur J Neurol 2009; 16:183-7. [ Links ]

    11. Cristiano E, Patrucco L, Giunta D, Videla G, Soriano ER, Rojas JI. Incidence of multiple sclerosis in Buenos Aires: a 16-year health maintenance organization-based study. Eur J Neurol 2010; 17: 479-82. [ Links ]

    12. Melcon MO, Vergara RH, Ceratto R. Prevalencia de Esclerosis Múltiple en Junín, Provincia de Buenos Aires, Argentina. Rev Neurol 1994; 19: 3-8. [ Links ]

    13. Melcon M, Gold L, Carra A, et al. Argentine Patagonia: prevalence and clinical features of multiple sclerosis. Mult Scler 2008; 14: 656-62. [ Links ]

    14. Cristiano E, Patrucco L, Garcea O, et al. Prevalence of multiple sclerosis in Argentina estimated by capture recapture method. J Neurol Sci 1999; 2: A438. [ Links ]

    15. Piedrabuena R, Giobellina R, Alvarez D, V A. High prevalence of multiple sclerosis in the city of Oliva, Cordoba, Argentina. Arq Neuropsiquiatr 2004; 62: 13. [ Links ]

    16. Cristiano E, Patrucco L, Carrá A, et al. Características clínico evolutivas de la esclerosis múltiple en Argentina. Estudio multicéntrico. Neurologia Argentina 1999; 24: 13. [ Links ]

    17. Sandoval G, Fernández Liguori N, Cáceres F, Sica R, Garcea O. Características de inicio en la esclerosis múltiple en recaídas y remisiones. Neurologia Argentina 2000; 25: 36. [ Links ]

    18. Sandoval G, Villa A, Vanotti S, Garcea M, Garcea O. Esclerosis Múltiple dos décadas de experiencia. Neurología Argentina 2004; 29: 16. [ Links ]

    19. Saladino L, Fernández Liguori N. Características clínico demográficas de una población con esclerosis múltiple en un Hospital público de Capital Federal. Neurología Argentina 2006; 31: 46. [ Links ]

    20. Rojas JI, Patrucco L, Riccio P, Cristiano E. Historia natural de la esclerosis múltiple: severidad de la enfermedad en una cohorte de Argentina. Neurologia Argentina 2008; 33: 7. [ Links ]

    21. Rojas JI, Patrucco L, Cristiano E. Historia natural de la esclerois múltiple primaria progresiva en Buenos Aires. Neurologia Argentina 2009; 1: 15. [ Links ]

    22. Vetere S, Muñiz R, Luisi AM, E. Esclerosis múltiple: análisis epidemiológico. Revista Neurológica 1998; 23: 3. [ Links ]

    23. Bardeci C, Cristiano E, Torres D, Serra P. Esclerosis múltiple: Datos epidemiológicos en 150 pacientes. Revista Neurológica Argentina 1994; 19:26. [ Links ]

    24. Caceres FS, Kremenchutzky MFL, Garcea O. Análisis de una población de pacientes con esclerosis múltiple. Revista Neurológica Argentina 1993; 21: 175. [ Links ]

    25. Bardeci C, Patrucco L, Torres D, Cristiano E. Consultorio de esclerosis múltiple, cinco años de experiencia. Revista Neurológica Argentina 1993; 21: 215. [ Links ]

    26. Ebers GC. Environmental factors and multiple sclerosis. Lancet Neurol 2008; 7: 268-78. [ Links ]

    27. Lauer K. Environmental associations with the risk of multiple sclerosis: the contribution of ecological studies. Acta Neurol Scand Suppl 1995;161: 77-88. [ Links ]

    28. Dolinoy DC, Jirtle RL. Environmental epigenomics in human health and disease. Environ Mol Mutagen 2008; 49: 4-8. [ Links ]

    29. Kurtzke JF. MS epidemiology world wide. One view of current status. Acta Neurol Scand Suppl 1995; 161: 23-33. [ Links ]

    30. Kurtzke JF. Epidemiology of multiple sclerosis. Does this really point toward an etiology? Lectio Doctoralis. Neurol Sci 2000; 21: 383-403. [ Links ]

    31. Orton SM, Herrera BM, Yee IM, et al. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol 2006; 5: 932-6. [ Links ]

    32. Kremenchutzky M, Rice GP, Baskerville J, Wingerchuk DM, Ebers GC. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain 2006; 129: 584-94. [ Links ]

    33. Weinshenker BG. The natural history of multiple sclerosis. Neurol Clin 1995; 13:119-46. [ Links ]

    1. Borrell Bentz R. La educación médica de posgrado en Argentina: el desafío de una nueva práctica educativa. 1 ed. Buenos Aires: OPS/OMS, 2005. [ Links ]

    2. Barousse AP. Certificación de profesionales médicos en la especialidad Clínica Médica. Medicina (B Aires) 2002; 62: 609-11. [ Links ]

    3. Accreditation Council for Graduate Medical Education ACGME Program Requirements for Residency Education in Internal Medicine http://www.acgme.org/acWebsite/downloads/RRC_progReq/140_im_07012007.pdf.; consultado julio 2007. [ Links ]

    4. Levine RB, Hebert RS, Wright SM. Resident research and scholarly activity in internal medicine residency training programs. J Gen Intern Med 2005; 20: 155-9. [ Links ]

    5. García GMG. Residencias del equipo de salud. Sistema Nacional de Acreditación de Residencias del Equipo de Salud. Criterios básicos. Integrantes del sistema. Registros, Min. Salud y Medio Ambiente. Dirección Nacional del Boletín Oficial: Buenos Aires, 2006. [ Links ]

    6. Elizondo CM, Giunta DH, González Bernaldo de Quirós F, et al. Residencias de medicina interna en Argentina, 2008. Medicina (B Aires) 2010; 70: 143-50. [ Links ]

    7. Van der Steen JT, Ooms ME, Ader HJ, Ribbe MW, van der Wal G. Withholding antibiotic treatment in pneumonia patients with dementia: a quantitative observational study. Arch Intern Med 2002; 162: 1753-60. [ Links ]

    8. Meyers FJ, Weinberger SE, Fitzgibbons JP, et al. Redesigning residency training in internal medicine: the consensus report of the Alliance for Academic Internal Medicine Education Redesign Task Force. Acad Med 2007; 82: 1211-9. [ Links ]

    9. Fletcher KE, Underwood W 3rd, Davis SQ, et al. Effects of work hour reduction on residents' lives: a systematic review. JAMA, 2005; 294: 1088-100. [ Links ]

    10. Hamann KL, Fancher TL, aint S, Henderson MC. Clinical research during internal medicine residency: a practical guide. Am J Med 2006; 119: 277-83. [ Links ]

    11. Alguire PC, Anderson WA, Albrecht RR, Poland GA. Resident research in internal medicine training programs. Ann Intern Med 1996; 124: 321-8. [ Links ]

    12. Vinci RJ, Bauchner H, Finkelstein J, et al. Research during pediatric residency training: outcome of a senior resident block rotation. Pediatrics 2009; 124: 1126-34. [ Links ]

    13. Kanna B, Deng C, Erickson SN, et al. The research rotation: competency-based structured and novel approach to research training of internal medicine residents. BMC Med Educ 2006; 6: 52. [ Links ]

    14. Rivera JA Levine RB, Wright SM. Completing a scholarly project during residency training. Perspectives of residents who have been successful. J Gen Intern Med 2005; 20: 366-9. [ Links ]

    15. Fuentes NA, Giunta DH, Pazo V, et al. Proyecto institucional para la educación médica continua en investigación clinica. Medicina (B Aires) 2010; 70: 240-6. [ Links ]

    16. Pereiro ND, Elizondo C, Giunta D, Figa S. Clinical Eepidemiologic Research in Internal Medicine Residencies in Argentina. Qualitative Study, in 29Th World Congress of Internal Medicine 2008: Buenos Aires. [ Links ]

    17. González García GM. Residencias del equipo de salud. Sistema Nacional de Acreditación de Residencias del Equipo de Salud. Criterios básicos. Integrantes del sistema. Registros. En: http://www.femeba.org.ar/fundacion/, Min. Salud y M. Ambiente, Dirección Nacional del Boletín Oficial: Buenos Aires, 2006. [ Links ]

    1. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007; 370: 890-907. [ Links ]

    2. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum 2007; 90: 1-636. [ Links ]

    3. Muñoz N, Bosch FX, de Sanjosé S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518-27. [ Links ]

    4. Bruni L, Díaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 2010; 202: 1789-99. [ Links ]

    5. Clifford GM, Smith JS, Aguado T, Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 2003; 89: 101-5. [ Links ]

    6. Arrossi S, Ramos S, Paolino M, Sankaranarayanan R. Social inequality in Pap smear coverage: identifying under-users of cervical cancer screening in Argentina. Reprod Health Matters 2008; 16: 50-8. [ Links ]

    7. Arrossi S. Proyecto para el mejoramiento del Programa Nacional de Prevención de Cáncer de Cuello Uterino en Argentina. Informe final: Diagnóstico de situación del Programa Nacional y Programas Provinciales. 1 ed. Buenos Aires: Organización Panamericana de la Salud, OPS; 2008. In: http://www.msal.gov.ar/cancer-cervico-uterino/pdf/info-equipos-salud/Diagnostico_Pub64_OPS.pdf (last accessed 14-11-2011). [ Links ]

    8. Bernard HU, Chan SY, Manos MM, et al. Identification and assessment of known and novel human papillomaviruses by polymerase chain reaction amplification, restriction fragment length polymorphisms, nucleotide sequence, and phylogenetic algorithms. J Infect Dis 1994; 170: 1077-85. [ Links ]

    9. Manos MM, Ting Y, Wright DK, Lewis AJ, Brocker TR, Wolinsky SM. The use of polymerase chain reaction amplification for the detection of genital human papillomavirus. Cancer Cells 1989; 7: 209-14. [ Links ]

    10. de Roda Husman AM, Walboomers JM, van den Brule AJ, Meijer CJ, Snijders PJ. The use of general primers GP5 and GP6 elongated at their 3' ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol 1995; 76 (Pt 4): 1057-62. [ Links ]

    11. Ho L, Chan SY, Burk RD, et al. The genetic drift of human papillomavirus type 16 is a means of reconstructing prehistoric viral spread and the movement of ancient human populations. J Virol 1993; 67: 6413-23. [ Links ]

    12. Picconi MA, Gronda J, Alonio LV, et al. Human Papilloma virus in Quechua women from Jujuy with high frequency of cervical cancer: viral types and HPV-16 variants. Medicina (B Aires) 2002; 62: 209-20. [ Links ]

    13. Tonon SA, Picconi MA, Zinovich JB, et al. Human papillomavirus cervical infection in Guarani Indians from the rainforest of Misiones, Argentina. Int J Infect Dis 2004; 8: 13-9. [ Links ]

    14. Soto-De Leon S, Camargo M, Sanchez R, et al. Distribution patterns of infection with multiple types of human papillomaviruses and their association with risk factors. PLoS One 2011; 6: e14705. [ Links ]

    15. Brito EB, Silva ID, Stávale JN, Taromaru E, Menezess RC, Martins SJ. Amerindian women of the Brazilian Amazon and STD. Eur J Gynaecol Oncol 2006; 27: 279-81. [ Links ]

    16. Kightlinger RS, Irvin WP, Archer KJ, et al. Cervical cancer and human papillomavirus in indigenous Guyanese women. Am J Obstet Gynecol 2010; 202: 626. e1-7. [ Links ]

    17. de Sanjosé S, Díaz M, Castellsagué X, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007; 7: 453-9. [ Links ]

    18. Parkin DM, Almonte M, Bruni L, Clifford G, Curado MP, Piñeros M. Burden and trends of type-specific human papillomavirus infections and related diseases in the Latin America and Caribbean region. Vaccine 2008; 26: L1-15. [ Links ]

    19. Almonte M, Albero G, Molano M, Carcamo C, García PJ, Pérez G. Risk factors for human papillomavirus exposure and co-factors for cervical cancer in Latin America and the Caribbean. Vaccine 2008; 26: L16-36. [ Links ]

    20. Lippman SA, Sucupira MCA, Jones HE, et al. Prevalence, distribution and correlates of endocervical human papillomavirus types in Brazilian women. Int J STD AIDS 2010; 21: 105-9. [ Links ]

    21. Franceschi S, Herrero R, Clifford GM, et al. Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer 2006; 119: 2677-84. [ Links ]

    22. Smith JS, Melendy A, Rana RK, Pimenta JM. Age-specific prevalence of infection with human papillomavirus in females: a global review. J Adolesc Health 2008; 43: S5-25, S25. e1-41. [ Links ]

    23. Franceschi S, Rajkumar R, Snijders PJF, et al. Papillomavirus infection in rural women in southern India. Br J Cancer 2005; 92: 601-6. [ Links ]

    24. Muñoz N, Méndez F, Posso H, et al. Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis 2004; 190: 2077-87. [ Links ]

    25. Tábora N, Bakkers JM, Quint WG, et al. Human papillomavirus infection in Honduran women with normal cytology. Cancer Causes Control 2009; 20: 1663-70. [ Links ]

    26. Spinillo A, Dal Bello B, Gardella B, Roccio M, Dacco MD, Silini EM. Multiple human papillomavirus infection and high grade cervical intraepithelial neoplasia among women with cytological diagnosis of atypical squamous cells of undetermined significance or low grade squamous intraepithelial lesions. Gynecol Oncol 2009; 113: 115-9. [ Links ]

    27. Trottier H, Mahmud S, Costa MC, et al. Human papillomavirus infections with multiple types and risk of cervical neoplasia. Cancer Epidemiol Biomarkers Prev 2006; 15: 1274-80. [ Links ]

    28. Bello BD, Spinillo A, Alberizzi P, et al. Cervical infections by multiple human papillomavirus (HPV) genotypes: Prevalence and impact on the risk of precancerous epithelial lesions. J Med Virol 2009; 81: 703-12. [ Links ]

    29. Sichero L, Ferreira S, Trottier H, et al. High grade cervical lesions are caused preferentially by non-European variants of HPVs 16 and 18. Int J Cancer 2007; 120: 1763-8. [ Links ]

    30. Xi LF, Koutsky LA, Hildesheim A, et al. Risk for high-grade cervical intraepithelial neoplasia associated with variants of human papillomavirus types 16 and 18. Cancer Epidemiol Biomarkers Prev 2007; 16: 4-10. [ Links ]

    31. Sichero L, Villa LL. Epidemiological and functional implications of molecular variants of human papillomavirus. Braz J Med Biol Res 2006; 39: 707-17. [ Links ]

    32. Tonon SA, Basiletti J, Badano I, et al. Human papillomavirus type 16 molecular variants in Guarani Indian women from Misiones, Argentina. Int J Infect Dis 2007; 11: 76-81. [ Links ]

    33. Picconi MA, Alonio LV, García Carrancá A, et al. Molecular variants of human papillomavirus (HPV) types 16 and 18 in adenocarcinomas of the cervix. Medicina (B Aires) 2000; 60: 889-94. [ Links ]

    34. Alencar TR, Cerqueira DM, da Cruz MR, Wyant PS, Ramalho ED, Martins CR. New HPV-16 European and non-European variants in Central Brazil. Virus Genes 2007; 35: 1-4. [ Links ]

    1. Ding EL, Hu FB. Smoking and type 2 diabetes: under recognized risks and disease burden. JAMA 2007; 298: 2675-6. [ Links ]

    2. Mathur RK. Role of diabetes, hypertension, and cigarette smoking on atherosclerosis. J Cardiovasc Dis Res 2010; 1: 64-8. [ Links ]

    3. Alanbaei M, Zubaid M, Al-Mallah MH, et al. Impact of diabetes and smoking epidemic in the Middle East on the presentation with acute coronary syndrome in very young patients. Angiology 2012; 63: 48-54. [ Links ]

    4. Matsubayashi H, Maeda A, Kanemoto H, et al. Risk factors of familial pancreatic cancer in Japan: current smoking and recent onset of diabetes. Pancreas 2011; 40: 974-8. [ Links ]

    5. Zedan H, Hareadei AA, Abd-Elsayed AA, Abdel-Maguid EM. Cigarette smoking, hypertension and diabetes mellitus as risk factors for erectile dysfunction in upper Egypt. East Mediterr Health J 2010; 16: 281-5. [ Links ]

    6. Cho NH, Chan JC, Jang HC, Lim S, Kim HL, Choi SH. Cigarette smoking is an independent risk factor for type 2 diabetes: a four-year community-based prospective study. Clin Endocrinol (Oxf) 2009; 71: 679-85. [ Links ]

    7. Fagard RH, Nilsson PM. Smoking and diabetes-the double health hazard! Prim Care Diabetes 2009; 3: 205-9. [ Links ]

    8. Currie LJ, Sharpe JR, Martin R. The use of fibrin glue in skin grafts and tissue-engineered skin replacements: a review. Plast Reconstr Surg 2001; 108: 1713-26. [ Links ]

    9. Heistein JB, Cook PA. Factors affecting composite graft survival in digital tip amputations. Ann Plast Surg 2003; 50: 299-303. [ Links ]

    10. Mowlavi A, Andrews K, Milner S, Herndon DN, Heggers JP. The effects of hyperglycemia on skin graft survival in the burn patient. Ann Plast Surg 2000; 45: 629-32. [ Links ]

    11. Ramos G, Guastavino MP, Bolgiani A, Prezzavento G. Patiño 0, Benaim F. Hypoalbuminemia in burned patients: an outcome marker that could define evolution periods. Revist Argent Quemad 2000; 15: 23-9. [ Links ]

    12. Vibe P, Pless J. A new method of skin graft adhesion. Scand J Plast Reconstr Surg 1983; 17: 263-4. [ Links ]

    1. Pernot F. La ruta de la seda. Londres: Parragon, 2001. [ Links ]

    2. Hyde N. Silk, the queen of textiles. National Geographic Magazine 1984; 65: 2-49. [ Links ]

    3. Wang X, Zhang X, Castellot J, Herman I, Iafrati M, Kaplan DL. Controlled release from multilayer silk biomaterial coatings to modulate vascular cell responses. Biomaterials 2008; 29: 894-903. [ Links ]

    4. Zhang J, Pritchard E, Hu X, et al. Stabilization of vaccines and antibiotics in silk and eliminating the cold chain. Proc Natl Acad Sci U S A 2012; 109: 11981-6. [ Links ]

    5. Larrán de Vere A. Franklin. Biblioteca Billiken, Buenos Aires Editorial Atlántida, 1945. [ Links ]

    1. De Costa C. St Anthony´s fire and living ligatures: a short history of ergotamine. Lancet 2002; 359: 1768-70. [ Links ]

    2. Ruano Calderón L, Zermeño Pohls F. Ergotismo. Presentación de un caso y revisión de la bibliografía. Revista de Neurología 2005; 40: 412-6. [ Links ]

    3. Baldwin Z, Ceraldi C. Ergotism associated with HIV antiviral protease inhibitor therapy. J Vasc Surg 2003; 37: 676-8. [ Links ]

    4. Rosenthal E, Sala F, Chichmanian R, et al. Ergotism related to concurrent administration of ergotamine tartrate and indinavir. JAMA 1999; 281: 987. [ Links ]

    5. Mortier E, Pouchot J, Vinceneux P, Lalande M. Ergotism related to interaction between nelfinavir and ergotamine. Am J Med 2001; 110: 594. [ Links ]

    6. Montero A, Giovannoni A, Tvrde, P. Leg ischemia in a patient receiving ritonavir and ergotamine. Ann Intern Med 1999; 130: 329. [ Links ]

    7. Blanche P, Rigolet A, Gombert B, Ginsburg C, Salmon D, Sicard D. Ergotism related to a single dose of ergotamine tartrato in an AIDS patient treated with ritonavir. Postgrad Med J 1999; 75: 546-8. [ Links ]

    8. Pardo Rey C, Yebra M, Borrallo M, Vega A, Ramos A, Montero M. Irreversible coma, ergotamine and ritonavir. Clin Infect Dis 2003; 37: 72-3. [ Links ]

    9. Spiegel M, Schmidauer C, Kampfl A, Sarcletti M, Poewe W. Cerebral ergotism under treatment with ergotamine and ritonavir. Neurology 2001; 57: 743. [ Links ]

    10. Frhlich G, Kaplan V, Amann-Vesti B. Holy fire in an HIV-positive man: a case of 21st-century Ergotism. CMAJ 2010; 182: 378-80. [ Links ]

    11. Vila A, Mykietiuk A, Bonvehí P, Temporiti A, Urueña A, Herrera F. Clinical ergotism induced by ritonavir. Scand J Infect Dis 2001; 33: 788-9. [ Links ]

    12. Caballero-Granado F, Viciana P, Cordero E, Gómez-Vera M, de Nozal M, López-Cortez L. Ergotism related to concurrent administration of ergotamine tartrate and ritonavir in an AIDS patient. Antimicrob Agents Chemother 1997; 45: 1207. [ Links ]

    13. Liaudet L, Buclin T, Jaccard C, Eckert P. Severe ergotism associated with interaction between ritonavir and ergotamine. BMJ 1999; 318: 771. [ Links ]

    14. Antopolsky M, Hiller N, Salameh S, Goldshtein B, Stalnikowicz R. Splenic infarction: 10 years of experience. Am J Emerg Med 2009; 27: 262-5. [ Links ]

    15. Yaacov R, Pokroy R, Berlowitz D, Aharoni D, Hain D, Breuer G. Splenic infarction: an update on William Osler´s observations. Isr Med Assoc J 2010; 12: 362-5. [ Links ]

    1. Faivre L, Collod-Beroud G, Loeys L, et al. Effect of mutation type and location on clinical outcome in 1,013 probands with Marfan syndrome or related phenotypes and FBN1 mutations: an international study. Am J Hum Genet 2007; 81: 454-66. [ Links ]

    2. Bolineau C, Jondeau G, Mizuguchi T, et al. Molecular genetics of Marfan syndrome. Curr Opin Cardiol 2005; 20: 194-200. [ Links ]

    3. Neptune E, Frinchmeyer PA, Arking DE, et al. Dysregulation of TFG-Beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet 2003; 33: 407-11. [ Links ]

    4. den Heijer M, Lewintong S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J Thromb Haemost 2005; 3: 292-9. [ Links ]

    5. Giusti B, Porciani M, Brunelli T, et al. Phenotypic variability of cardiovascular manifestations in Marfan syndrome, possible role of hyperhomocysteinemia and C677T MTHFR gene polymorphism. European Heart Journal 2003; 24: 2038-45. [ Links ]

    6. Loeys B, Dietz H, Braverman A, et al. The revised Ghent nosology for the Marfan syndrome. J Med Genet 2010; 47: 476-85. [ Links ]

    7. Hiroshi Matsuo: Clinical significance and impact of "painless acute aortic dissection". Official Journal of the Japanese Circulation Society 2011; 75: 47-8. [ Links ]

    8. Jeremy, RW, Huang H, Hwa J, et al. Relation between age, arterial distensibility and aortic dilatation in the Marfan syndrome. Am J cardiol 1994; 74: 369-73. [ Links ]

    9. Stanger O, Herman W, Pietrzik K, et al. Clinical use rational management of homocysteine, folic acid, and B vitamins in cardiovascular and thrombotic diseases. Z Kardiol 2004; 93: 439-53. [ Links ]

    10. Zittan E, Preis M, Asmir I, et al. High frequency of vitamin B12 deficiency in asymptomatic individuals homocygous to MTHFR C677T mutation is associated whit endothelial dysfunction and homocysteinemia. Am J Physiol Heart Circ Physiol 2007; 293: 860-5. [ Links ]

    1. Rabagliati R, Fuentes LG, Guzmán AM, et al. Enfermedad fúngica invasora en pacientes hemato-oncológicos y receptores de trasplante de precursores hematopoyéticos bajo la perspectiva de los criterios diagnósticos EORTC/MSG. Rev Chilena Infectol 2009; 26: 212-9. [ Links ]

    2. Pagano L, Caira M, Candoni A, et al. Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. Haematologica 2010; 95: 644-50. [ Links ]

    3. Barnes PD, Marr KA. Aspergillosis: spectrum of disease, diagnosis, and treatment. Infect Dis Clin North Am 2006; 20: 545-61. [ Links ]

    4. Galimberti R, Kowalczuk A, Hidalgo Parra I, Gonzalez Ramos G, Flores V. Cutaneous aspergillosis: a report of six cases. Br J Dermatol 1998; 139: 522-6. [ Links ]

    5. Nakashima K, Yamada N, Yoshida Y, Yamamoto O. Primary cutaneous aspergillosis. Acta Derm Venereol 2010; 90: 519-20. [ Links ]

    6. Nucci M, Anaissie E. Fungal infections in hematopoietic stem cell transplantation and solid-organ transplantation: focus on aspergillosis. Clin Chest Med 2009; 30: 295-306. [ Links ]

    7. Martinez R, Castro G, Machado AA, Moya MJ. Primary aspergilloma and subacute invasive aspergillosis in two AIDS patients. Rev Inst Med Trop Sao Paulo 2009; 51: 49-52. [ Links ]

    8. Zhang QQ, Li L, Zhu M, Zhang CY, Wang JJ. Primary cutaneous aspergillosis due to Aspergillus flavus: a case report. Chin Med J 2005; 118: 255-7. [ Links ]

    9. Yuanjie Z, Jingxia D, Hai W, Jianghan C, Julin G. Primary cutaneous aspergillosis in a patient with cutaneous T-cell lymphoma. Mycoses 2008; 52: 462-4. [ Links ]

    10. Abbasi S, Shenep JL, Hughes WT, Flynn PM. Aspergillosis in children with cancer: A 34-year experience. Clin Infect Dis 1999; 29: 1210-9. [ Links ]

    11. Grossman ME, Fithian EC, Behrens C, Bissinger J, Fracaro M, Neu HC. Primay cutaneous aspergillosis in six leukemic children. J Am Acad Dermatol 1985; 12: 313-8. [ Links ]

    12. Horvath JA, Dummer S. The use of respiratory-tract cultures in the diagnosis of invasive pulmonary aspergillosis. Am J Med 1996; 100: 171-8. [ Links ]

    13. Wheat LJ. Approach to the diagnosis of invasive aspergillosis and candidiasis. Clin Chest Med 2009; 30: 367-77. [ Links ]

    14. Tunccan G, Aki SZ, Akyrek N, Sucak G, Senol E. Isolated cutaneous aspergillosis in an acute lymphoblastic leukemia patient after allogeneic stem cell transplantation. J Infect Dev Ctries 2011; 5: 406-9. [ Links ]

    1. Gonzales R, Steiner JF, Lum A, Barrett PH Jr. Decreasing antibiotic use in ambulatory practice: impact of a multidimensional intervention on the treatment of uncomplicated acute bronchitis in adults. JAMA 1999; 281: 1512-9. [ Links ]

    2. Gross PA, Barrett TL, Dellinger P, et al. Purpose of quality standards for infectious diseases. Infectious Diseases Society of America. Clin Infect Dis 1994; 18: 4. [ Links ]

    3. Schappert SM, Rechtsteiner EA. Ambulatory medical care utilization estimates for 2006. Natl Health Stat Report 2008; 8: 1-29. [ Links ]

    4. Bisno AL, Gerber MA, Gwaltney JM Jr, Kaplan EL, Schwartz RH. Practice guidelines for the diagnosis and management of group A streptococcal pharyngitis. Infectious Diseases Society of America. Clin Infect Dis 2002; 35: 113-25. [ Links ]

    5. Villar H, Jugo M, Santana G, Baserni M, Reil J. Aumento en la prevalencia de Streptococcus beta hemolíticos en hisopados faríngeos en Buenos Aires. Medicina (B Aires) 2005; 65: 311-4. [ Links ]

    6. Snow V, Mottur-Pilson C, Cooper RJ, Hoffman JR. Principles of appropriate antibiotic use for acute pharyngitis in adults. Ann Intern Med 2001; 134: 506-8. [ Links ]

    7. Alcaide ML, Bisno AL. Pharyngitis and epiglottitis. Infect Dis Clin North Am 2007; 21: 449-69. [ Links ]

    8. Cooper RJ, Hoffman JR, Bartlett JG, et al. Principles of appropriate antibiotic use for acute pharyngitis in adults: background. Ann Intern Med 2001; 134: 509-17. [ Links ]

    9. McIsaac WJ, Kellner JD, Aufricht P, Vanjaka A, Low DE. Empirical validation of guidelines for the management of pharyngitis in children and adults. JAMA 2004; 291: 1587-95. [ Links ]

    10. Centor RM, Witherspoon JM, Dalton HP, Brody CE, Link K. The diagnosis of strep throat in adults in the emergency room. Med Decis Making 1981; 1: 239-46. [ Links ]

    11. Halfon ST, Davies AM, Kaplan O, Lazarov E, Bergner- Rabinowitz S. Primary prevention of rheumatic fever in Jerusalem schoolchildren. 2. Identification of beta-hemolytic streptococci. Isr J Med Sci 1968; 4: 809-14. [ Links ]

    12. Bisno AL. Diagnosing strep throat in the adult patient: do clinical criteria really suffice? Ann Intern Med 2003; 139: 150-1. [ Links ]

    13. Gieseker KE, Mackenzie T, Roe MH, Todd JK. Comparison of two rapid Streptococcus pyogenes diagnostic tests with a rigorous culture standard. Pediatr Infect Dis J 2002; 21: 922-7. [ Links ]

    14. Gerber MA, Shulman ST. Rapid diagnosis of pharyngitis caused by group A streptococci. Clin Microbiol Rev 2004; 17: 571-80. [ Links ]

    15. Krober MS, Bass JW, Michels GN. Streptococcal pharyngitis. Placebo-controlled double-blind evaluation of clinical response to penicillin therapy. JAMA 1985; 253: 1271-4. [ Links ]

    16. Del Mar C, Glasziou PP, Spinks AB. Antibiotics for sore throat. Cochrane Database Syst Rev 2006; CD000023. [ Links ]

    17. Robertson KA, Volmink JA, Mayosi BM. Antibiotics for the primary prevention of acute rheumatic fever: a meta-analysis. BMC Cardiovasc Disord 2005; 5: 11. [ Links ]

    18. Regoli M, Chiappini E, Bonsignori F, Galli L, de Martino M. Update on the management of acute pharyngitis in children. Ital J Pediatr 2011; 37: 10. [ Links ]

    19. Thomas M, Del Mar C, Glasziou P. How effective are treatments other than antibiotics for acute sore throat? Br J Gen Pract 2000; 50: 817-20. [ Links ]

    20. Korb K, Scherer M, Chenot JF. Steroids as adjuvant therapy for acute pharyngitis in ambulatory patients: a systematic review. Ann Fam Med 2010; 8: 58-63. [ Links ]

    21. Hayward G, Thompson M, Heneghan C, Perera R, Del Mar C, Glasziou P. Corticosteroids for pain relief in sore throat: systematic review and meta-analysis. BMJ 2009; 339: b2976. [ Links ]

    22. Schutz A, Gund HJ, Pschorn U, et al. Local anaesthetic properties of ambroxol hydrochloride lozenges in view of sore throat. Clinical proof of concept. Arzneimittelforschung 2002; 52: 194-9. [ Links ]

    23. Fischer J, Pschorn U, Vix JM, et al. Efficacy and tolerability of ambroxol hydrochloride lozenges in sore throat. Randomised, double-blind, placebo-controlled trials regarding the local anaesthetic properties. Arzneimittelforschung 2002; 52: 256-63. [ Links ]

    24. Wessels MR. Clinical practice. Streptococcal pharyngitis. N Engl J Med 2011; 364: 648-55. [ Links ]

    25. Feder HM Jr, Gerber MA, Randolph MF, Stelmach PS, Kaplan EL. Once-daily therapy for streptococcal pharyngitis with amoxicillin. Pediatrics 1999; 103: 47-51. [ Links ]

    26. Shvartzman P, Tabenkin H, Rosentzwaig A, Dolginov F. Treatment of streptococcal pharyngitis with amoxycillin once a day. BMJ 1993; 306: 1170-2. [ Links ]

    27. Gerber MA, Baltimore RS, Eaton CB, et al. Prevention of rheumatic fever and diagnosis and treatment of acute streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation 2009; 119: 1541-51. [ Links ]

    28. Pichichero ME. Treatment and prevention of streptococcal tonsillopharyngitis. In: UpToDate, Dexton DJ, Edwards MS (Ed), UpToDate 2010. [ Links ]

    29. Kaplan EL, Gastanaduy AS, Huwe BB. The role of the carrier in treatment failures after antibiotic for group A streptococci in the upper respiratory tract. J Lab Clin Med 1981; 98: 326. [ Links ]

    30. Tanz RR, Shulman ST. Streptococcal pharyngitis: the carrier state, definition, and management. Pediatr Ann 1998; 27: 281-5. [ Links ]

    31. Centers for Disease Control and Prevention, Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep. 2006; 55: 1-94. [ Links ]

    32. García S, Casco R, Perazzi B, De Mier C, Vay C, Famiglietti A. Resistencia de Neisseria gonorrhoeae a ciprofloxacina según hábitos sexuales. Medicina (B Aires) 2008; 68: 358-62. [ Links ]

    33. American Academy of Pediatrics, Subcommittee on Management of Acute Otitis Media. Diagnosis and Management of Acute Otitis Media. Pediatrics 2004; 113: 1451-65. [ Links ]

    34. Lous J, Burton MJ, Felding JU, Ovesen T, Rovers MM, Williamson I. Grommets (ventilation tubes) for hearing loss associated with otitis media with effusion in children. Cochrane Database Syst Rev. 2005; CD001801. [ Links ]

    35. American Academy of Family Physicians; American Academy of Otolaryngology-Head and Neck Surgery; American Academy of Pediatrics Sub-committee on Otitis Media with Effusion. Otitis media with effusion. Pediatrics 2004; 113: 1412-29. [ Links ]

    36. Paradise JL, Rockette HE, Colborn DK, et al. Otitis media in 2253 Pittsburgh-area infants: prevalence and risk factors during the first two years of life. Pediatrics 1997; 99: 318-33. [ Links ]

    37. Gould JM, Matz PS. Otitis media. Pediatr Rev. 2010; 31: 102-16. [ Links ]

    38. López E, Vázquez M, Orlando N, et al. Streptococcus pneumoniae causing acute otitis media (aom): dynamic of serotype distribution in Buenos Aires, Argentina. Poster presentado en: 7th International Symposium on Pneumococci and Pneumococcal Diseases; 2010 March 14-18; Tel Aviv, Israel. [ Links ]

    39. Scottish Intercollegiate Guidelines Network. Diagnosis and management of childhood otitis media in primary care. February 2003 En: http://www.sign.ac.uk/pdf/sign66.pdf; consultado 26/11/2010. [ Links ]

    40. Coker TR, Chan L, Newberry S, et al. Diagnosis, microbial epidemiology, and antibiotic treatment of acute otitis media in children. A Systematic Review. JAMA 2010; 304: 2161-9. [ Links ]

    41. Flynn CA, Griffin GH, Schultz JK. Descongestants and antihistamines for acute otitis media in children. Cochrane Database Syst Rev 2004; CD001727. [ Links ]

    42. Van Zuijlen DA, Schilder AG, Van Balen FA, Hoes AW. National differences in incidence of acute mastoiditis: relationship to prescribing patterns of antibiotics for acute otitis media? Pediatr Infect Dis J 2001; 20: 140-4. [ Links ]

    43. Bezáková N, Damoiseaux RA, Hoes AW, Schilder AG, Rovers MM. Recurrence up to 3.5 years after antibiotic treatment of acute otitis media in very young Dutch children: survey of trial participants BMJ 2009; 338: b 2525. [ Links ]

    44. National Institute for Health and Clinical Excellence. Prescribing of antibiotics for self limiting respiratory tract infections in adults and children in primary care. 2008 (Clinical guideline 69) En: www.nice.org.uk/CG69; consultado 26/11/2010 [ Links ]

    45. Sanders SL, Glasziou PP, Del Mar C, Rovers M. Antibiotics for acute otitis media in children (Review) Cochrane Database Syst Rev 2009; 1-43. [ Links ]

    46. Cates C, Dr Chris Cates' EBM Web Site. En: www.nntonline.net; consultado 11/03/2011 [ Links ]

    47. Fossati S, Gagetti P, Reijtman V, et al and the Sireva-II Working Group-Argentina. Serotype distribution, antibiotic resistance and coverage of pneumococcal conjugate vaccines (PCV) before their introduction in the National Schedule: Argentina 2000-2011 Póster presentado en: 8th International Symposium on Pneumococci and Pneumococcal Diseases; 2012 March 11-15; Foz de Iguazú, Brasil. [ Links ]

    48. Dowell SF, Butler JC, Giebink GS, et al.Acute otitismedia: management and surveillance in an era of pneumococcal resistance- a report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group. Pediatr Infect Dis J 1999; 18: 1-9. [ Links ]

    49. Kozyrskyj A, Klassen TP, Moffatt M, Harvey K. Short-course antibiotics for acute otitis media. Cochrane Database Syst Rev 2010; CD001095. [ Links ]

    50. Gwaltney JM Jr. Acute community-acquired sinusitis. Clin Infect Dis 1996; 23: 1209-23. [ Links ]

    51. Gwaltney J. The 10 most common questions about the common cold. Infect Dis Clin Pract 1996; 5: 371-2. [ Links ]

    52. Hickner JM, Bartlett JG, Besser RE, et al. Principles of appropriate antibiotic use for acute rhinosinusitis in adults: background. Ann Intern Med 2001; 134: 498-505. [ Links ]

    53. Rosenfeld RM, Andes, D, Bhattacharyya, N, et al. Clinical practice guideline: adult sinusitis. Otolaryngol Head Neck Surg 2007; 137: S1-31. [ Links ]

    54. Bartlett J. IDCP Guidelines: Management of Upper Respiratory Tract Infections - Colds. Infect Dis Clin Pract 1997; 6: 212-6. [ Links ]

    55. Benninger MS, Segreti J. Is it bacterial or viral? Criteria for distinguishing bacterial and viral infections. J Fam Pract 2008; 57: S5-11. [ Links ]

    56. Gwaltney JM, Wiesinger B, Patrie J. Acute community-acquired bacterial sinusitis: the value of antimicrobial treatment and the natural history. Clin Infect Dis 2004; 38: 227-33. [ Links ]

    57. Hansen JG, Schmidt H, Rosbor J, Lund E. Predicting acute maxillary sinusitis in a general practice population. BMJ 1995; 311: 233-6. [ Links ]

    58. Anon JB, Jacobs MR, Poole MD, et al and the Sinus and Allergy Health Partnership (SAHP). Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg 2004; 130: S1- 45. [ Links ]

    59. Meltzer EO, Hamilos DL, Hadley JA, et al. Rhinosinusitis: establishing definitions for clinical research and patient care. Otolaryngol Head Neck Surg 2004; 131: S1-62. [ Links ]

    60. Slavin RG, Spector SL, Bernstein IL, et al. The diagnosis and management of sinusitis: a practice parameter update. J Allergy Clin Immunol 2005; 116: S13-47. [ Links ]

    61. Williams JW Jr, Simel DL, Roberts L, Samsa GP. Clinical evaluation for sinusitis. Making the diagnosis by history and physical examination. Ann Intern Med 1992; 117: 705-10. [ Links ]

    62. Lindbaek M, Hjortdahl P. The clinical diagnosis of acute purulent sinusitis in general practice-a review. Br J Gen Pract 2002; 52: 491-5. [ Links ]

    63. Ramanan R, Khan AN. Sinusitis Imaging. En: http://emedicine.medscape.com/article/384649; consultado 27/2/2011 [ Links ]

    64. Benninger MS, Appelbaum PC, Denneny JC, Osguthorpe DJ, Stankiewicz JA. Maxillary sinus puncture and culture in the diagnosis of acute rhinosinusitis: the case for pursuing alternative culture methods. Otolaryngol Head Neck Surg 2002; 127: 7-12. [ Links ]

    65. Ahovuo-Saloranta A, Borisenko OV, Kovanen N, et al. Antibiotics for acute maxillary sinusitis. Cochrane Database Syst Rev 2008, CD000243. [ Links ]

    66. National Institute for Health and Clinical Excellence. Prescribing of antibiotics for self limiting respiratory tract infections in adults and children in primary care. 2008. (Clinical guideline 69). En: www.nice.org.uk/CG69; consultado 27/2/2011. [ Links ]

    67. Young J, De Sutter A, Merenstein D, et al. Antibiotics for adults with clinically diagnosed acute rhinosinusitis: a meta-analysis of individual patient data. Lancet 2008; 371: 908-14. [ Links ]

    68. Piccirillo JF, Mager DE, Frisse ME, Brophy RH, Goggin A. Impact of first-line vs. second-line antibiotics for the treatment of acute uncomplicated sinusitis. JAMA 2001; 286: 1849-56. [ Links ]

    69. Karageorgopoulos DE, Giannopoulou KP, Grammatikos AP, Dimopoulos G, Falagas ME. Fluoroquinolones compared with beta-lactam antibiotics for the treatment of acute bacterial sinusitis: a meta-analysis of randomized controlled trials. CMAJ 2008; 178: 845-54. [ Links ]

    70. Guías para el Diagnóstico y Tratamiento de las Infecciones Respiratorias Altas elaboradas por la Subcomisión de Uso Apropiado de Recursos de la Sociedad Argentina de Infectología (SADI) Guías para el Diagnóstico y Tratamiento de las Infecciones Rinosinusales Agudas. En: http://www.sadi.org.ar/; consultado 27/2/2011. [ Links ]

    71. Desrosiers M, Frenkiel S, Hamid QA, et al. Acute bacterial sinusitis in adults: management in the primary care setting. J Otolaryngol 2002; 31: 2S 2-14. [ Links ]

    72. Agence Française de Sécurité Sanitaire des Produits de Santé. Systemic antibiotic treatment in upper and lower respiratory tract infections: official French guidelines. Clin Microbiol Infect 2003; 9: 1162-78. [ Links ]

    73. Benninger MS, Desrosiers M, Klossek JM. Management of Acute Bacterial Rhinosinusitis Current Issues and Future Perspectives. Int J Clin Pract 2006; 60: 190-200. [ Links ]

    74. Organización Panamericana de la Salud. Guía para el tratamiento de las enfermedades infecciosas. Washington D.C: OPS, 2004. [ Links ]

    75. Worral G. Acute Sinusitis. Can Fam Physician 2008; 54: 82-3. [ Links ]

    76. Falagas ME, Karageorgopoulos DE, Grammatikos AP, Matthaiou DK. Effectiveness and safety of short vs. long duration of antibiotic therapy for acute bacterial sinusitis: a meta-analysis of randomized trials. Br J Clin Pharmacol 2009; 67: 161-71. [ Links ]

    77. Zalmanovici A, Yaphe J. Intranasal steroids for acute sinusitis. Cochrane Database Syst Rev. 2009; CD005149. [ Links ]

    1. Hynes RO. The extracellular matrix: not just pretty fibrils. Science 2009; 326: 1216-9. [ Links ]

    2. Gross J, Lapierre CM. Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc Natl Acad Sci USA 1962; 45: 1014-22. [ Links ]

    3. Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 2007; 8: 221-33. [ Links ]

    4. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006; 69: 562-73. [ Links ]

    5. Moore CS, Crocker SJ. An alternative perspective on the roles of TIMPs and MMPs in pathology. Am J Pathol 2012; 180: 12-6. [ Links ]

    6. Gill SE, Parks WC. Metalloproteinases and their inhibitors: regulators of wound healing. Int J Biochem Cell Biol 2008; 40: 1334-47. [ Links ]

    7. Manicone AM, Mc Guire JK. Matrix metalloproteinases as modulators of inflammation. Semin Cell Dev Biol 2008; 19: 34-41. [ Links ]

    8. Newby AC. Matrix metalloproteinase inhibition therapy for vascular diseases. Vascul Pharmacol 2012; 56: 232-44 [ Links ]

    9. Harper E and Bloch KJ. The zymogen of tadpole collagenase. Biochemistry 1971; 10: 3041-55. [ Links ]

    10. Arvelo F, Cotte C. Metalloproteinases in tumor progression. Invest Clin. 2006; 47: 185-205. [ Links ]

    11. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function and biochemistry. Circ Res 2003; 92: 827-39. [ Links ]

    12. Cascales Angosto M, Alvarez-Gómez JA. Metaloproteinasas, matriz extracelular y cáncer. An R Acad Nac Farm 2010; 76: 59-84. [ Links ]

    13. Flores-Reséndiz D, Castellanos-Juárez E, Benítez-Bribiesca L. Proteases in cancer progression. Gac Med Mex 2009;145: 131-42. [ Links ]

    14. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010; 141: 52-67. [ Links ]

    15. Edwards DR, Handsley MM, Pennington CJ. The ADAM metalloproteinases. Mol Aspects Med 2008; 29: 258-89. [ Links ]

    16. Roy R, Wewer U, Moses M. Exploring the role of ADAM 12 in breast cancer. AACR Meeting Abstracts 2006: 1025. [ Links ]

    17. Xiao LJ, Lin P, Lin F, et al. ADAM17 targets MMP-2 and MMP-9 via EGFR-MEK-ERK pathway activation to promote prostate cancer cell invasion. Int J Oncol 2012; 40: 1714-24. [ Links ]

    18. Ito I, Fixman ED, Asai K, et al. Platelet-derived growth factor and transforming growth factor-beta modulate the expression of matrix metalloproteinases and migratory function of human airway smooth muscle cells. Clin Exp Allergy 2009; 39: 1370-80. [ Links ]

    19. Park CH, Chung JH. Epidermal growth factor-induced matrix metalloproteinase-1 expression is negatively regulated by p38 MAPK in human skin fibroblasts. J Dermatol Sci 2011; 64: 134-41. [ Links ]

    20. Stetler-Stevenson WG. The tumor microenvironment: regulation by MMP-independent effects of tissue inhibitor of metalloproteinases-2. Cancer Metastasis Rev 2008; 27: 57-66. [ Links ]

    21. Hagemann T, Robinson SC, Schulz M, Trmper L, Balkwill FR, Binder C. Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-alpha dependent up-regulation of matrix metalloproteases. Carcinogenesis 2004; 25: 1543-9. [ Links ]

    22. Lee YA, Choi HM, Lee SH, et al. Hypoxia differentially affects IL-1-stimulated MMP-1 and MMP-13 expression of fibroblast-like synoviocytes in an HIF-1a-dependent manner. Rheumatology (Oxford) 2012; 51: 443-50. [ Links ]

    23. Schmucker AC, Wright JB, Cole MD, Brinckerhoff CE. Distal interleukin-1 (IL-1) response element of human matrix metalloproteinase-13 (MMP-13) binds activator protein 1 (AP-1) transcription factors and regulates gene expression. J Biol Chem 2012; 287: 1189-97. [ Links ]

    24. Lambert E, Dassé E, Haye B, Petitfrère E. TIMPs as multifacial proteins. Crit Rev Oncol Hematol 2004; 49: 187-98. [ Links ]

    25. Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 2002; 115: 3719-27. [ Links ]

    26. Fernández CA, Butterfield C, Jackson G, Moses MA. Structural and functional uncoupling of the enzymatic and angiogenic inhibitory activities of tissue inhibitor of metalloproteinase-2 (TIMP-2): loop 6 is a novel angiogenesis inhibitor. J Biol Chem 2003; 278: 40989-95. [ Links ]

    27. Bourboulia D, Stetler-Stevenson WG. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion. Semin Cancer Biol 2010; 20: 161-8. [ Links ]

    28. Van Damme J, Struyf S, Opdenakker G. Chemokine-protease interaccions in cancer. Semin Cancer Biol 2004; 14: 201-8. [ Links ]

    29. García MF, González-Reyes S, González LO, et al. Comparative study of the expression of metalloproteases and their inhibitors in different localizations within primary tumours and in metastatic lymph nodes of breast cancer. Int J Exp Pathol 2010; 91: 324-34. [ Links ]

    30. Chang C, Werb Z. The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol 2001; 11: S37-43. [ Links ]

    31. Omachi TA, Eisner MD, Rames A, Markovtsova L, Blanc PD. Matrix metalloproteinase-9 predicts pulmonary status declines in a1-antitrypsin deficiency. Respir Res 2011; 23: 12:35. [ Links ]

    32. Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 2011; 278: 16-27. [ Links ]

    33. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980; 284: 67-8. [ Links ]

    34. Noël A, Jost M, Maquoi E. Matrix metalloproteinases at cancer tumor-host interface. Semin Cell Dev Biol 2008; 19: 52-60. [ Links ]

    35. Witz IP. Tumor-microenvironment interactions: dangerous liaisons. Adv Cancer Res 2008; 100: 203-29. [ Links ]

    36. Hua H, Li M, Luo T, Yin Y, Jiang Y. Matrix metalloproteinases in tumorigenesis: an evolving paradigm. Cell Mol Life Sci 2011; 68: 3853-68. [ Links ]

    37. Chabottaux V, Noel A. Breast cancer progression: insights into multifaceted matrix metalloproteinases. Clin Exp Metastasis 2007; 24: 647-56. [ Links ]

    38. Decock J, Hendrickx W, Vanleeuw U, et al. Plasma MMP1 and MMP8 expression in breast cancer: protective role of MMP8 against lymph node metastasis. BMC Cancer 2008; 8: 77. [ Links ]

    39. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2: 161-74. [ Links ]

    40. Gonzalez LO, Corte MD, Vazquez J, et al. Study of matrix metalloproteinases and their tissue inhibitors in ductal in situ carcinomas of the breast. Histopathology 2008; 53: 403-15. [ Links ]

    41. Rucci N, Sanita P, Angelucci A. Expanding View of the Role of Matrix Metalloproteases in Metastatic Growth. Curr Mol Med 2011; 11: 609-22. [ Links ]

    42. Sun J. Matrix metalloproteinases and tissue inhibitor of metalloproteinases are essential for the inflammatory response in cancer cells. J Signal Transduct 2010; 2010: 985132. [ Links ]

    43. Sounni NE, Paye A, Host L, Noël A. MT-MMPS as regulators of vessel stability associated with angiogenesis. Front Pharmacol 2011; 2: 111. [ Links ]

    44. Patterson BC, Sang QA. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/Type IV collagenase (MMP-9). J Biol Chem 1997; 272: 28823-25. [ Links ]

    45. Lin HC, Chang JH, Jain S, et al. Matrilysin cleavage of corneal collagen type XVIII NC1 domain and generation of a 28-kDa fragment. Invest Ophthalmol Vis Sci 2001; 42: 2517-24. [ Links ]

    46. Kvelborg M, Sanjay A, Frohlich C, Alberchtsen R, Wewer U. ADAM 12 and SRC interactions in cancer. Proc Amer Assoc Cancer Res 2006; 47: 395. [ Links ]

    47. Mochizuki S, Tanaka R, Shimoda M, et al. Connective tissue growth factor is a substrate of ADAM28. Biochem Biophys Res Commun 2010; 402: 651-7. [ Links ]

    48. Ohtsuka T, Shiomi T, Shimoda M, et al. ADAM28 is over-expressed in human non-small cell lung carcinomas and correlates with cell proliferation and lymph node metastasis. Int J Cancer 2006; 118: 263-73. [ Links ]

    49. Giannelli G, Erriquez R, Fransvea E,et al. Proteolytic imbalance is reversed after therapeutic surgery in breast cancer patients. Int J Cancer 2004; 109: 782-5. [ Links ]

    50. Jiang Y, Goldberg ID, Shi YE. Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 2002; 21: 2245-52. [ Links ]

    51. Figueira RC, Gomes LR, Neto JS, Silva FC, Silva ID, Sogayar MC. Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential. BMC Cancer 2009; 9: 20. [ Links ]

    52. Del Casar JM, González LO, Alvarez E, et al. Comparative analysis and clinical value of the expression of metalloproteases and their inhibitors by intratumor stromal fibroblasts and those at the invasive front of breast carcinomas. Breast Cancer Res Treat 2009; 116: 39-52. [ Links ]

    53. Jinga DC, Blidaru A, Condrea I, et al. MMP-9 and MMP-2 gelatinases and TIMP-1 and TIMP-2 inhibitors in breast cancer: correlations with prognostic factors. J Cell Mol Med 2006; 10: 499-510. [ Links ]

    54. Wang BQ, Zhang CM, Gao W, Wang XF, Zhang HL, Yang PC. Cancer-derived matrix metalloproteinase-9 contributes to tumor tolerance. J Cancer Res Clin Oncol 2011; 137: 1525-33. [ Links ]

    55. Vizoso FJ, González LO, Corte MD, et al. Study of matrix metalloproteinases and their inhibitors in breast cancer. Br J Cancer 2007; 96: 903-11. [ Links ]

    56. Kim HJ, Park CI, Park BW, Lee HD, Jung WH. Expression of MT-1 MMP, MMP2, MMP9 and TIMP2 mRNAs in ductal carcinoma in situ and invasive ductal carcinoma of the breast. Yonsei Med J 2006; 47: 333-42. [ Links ]

    57. Têtu B, Brisson J, Wang CS, et al. The influence of MMP- 14, TIMP-2 and MMP-2 expression on breast cancer prognosis. Breast Cancer Res 2006; 8: R28. [ Links ]

    58. Del Casar JM, González-Reyes S, González LO, et al. Expression of metalloproteases and their inhibitors in different histological types of breast cancer. J Cancer Res Clin Oncol 2010; 136: 811-9. [ Links ]

    59. González LO, González-Reyes S, Junquera S, et al. Expression of metalloproteases and their inhibitors by tumor and stromal cells in ductal carcinoma in situ of the breast and their relationship with microinvasive events. J Cancer Res Clin Oncol 2010; 136: 1313-21. [ Links ]

    60. Patel S, Sumitra G, Koner BC, Saxena A. Role of serum matrix metalloproteinase-2 and -9 to predict breast cancer progression. Clinical Biochemistry 2011; 44: 869-72. [ Links ]

    61. Zhang B, Cao X, Liu Y, et al. Tumor-derived Matrix Metalloproteinase- 13 (MMP-13) correlates with poor prognoses of invasive breast cancer. BMC Cancer 2008; 8: 83-93. [ Links ]

    62. Liu XW, Taube ME, Jung KK, et al. Tissue inhibitor of metalloproteinase- 1 protects human breast epithelial cells from extrinsic cell death: a potential oncogenic activity of tissue inhibitor of metalloproteinase-1. Cancer Res 2005; 65: 898-906. [ Links ]

    63. Mylona E, Magkou C, Giannopoulou I, et al. Expression of tissue inhibitor of matrix metalloproteinases (TIMP)-3 protein in invasive breast carcinoma: relation to tumor phenotype and clinical outcome. Breast Cancer Res 2006; 8: R57. [ Links ]

    64. Surlin V, Ioana M, Pleşea IE. Genetic patterns of metalloproteinases and their tissular inhibitors - clinicopathologic and prognostic significance in colorectal cancer. Rom J Morphol Embryol 2011; 52: 231-6. [ Links ]

    65. Hong SW, Kang YK, Lee B, et al. Matrix metalloproteinase- 2 and -7 expression in colorectal cancer. J Korean Soc Coloproctol 2011; 27: 133-9. [ Links ]

    66. Alakus H, Grass G, Hennecken JK, et al. Clinicopathological significance of MMP-2 and its specific inhibitor TIMP-2 in gastric cancer. Histol Histopathol 2008; 23: 917-23. [ Links ]

    67. Shao W, Wang W, Xiong XG, et al. Prognostic impact of MMP-2 and MMP-9 expression in pathologic stage IA nonsmall cell lung cancer. J Surg Oncol 2011; 104: 841-6. [ Links ]

    68. Klein T, Bischoff R. Physiology and pathophysiology of matrix metalloproteases. Amino Acids 2011; 41: 271-90. [ Links ]

    69. Kim EM, Hwang O. Role of matrix metalloproteinase-3 in neurodegeneration. J Neurochem 2011; 116: 22-32. [ Links ]

    70. Diaz RJ, Eichten A, de Visser KE, Coussens LM. Matrix Metalloproteinases: mediators of tumour-host cell interactions. In: GG Meadows, ed. Integration/ Interaction of Oncologic Growth, N.York: Springer, 2005, 81-126. [ Links ]

    71. Bauvois B. New facets of matrix metalloproteinases MMP- 2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. Biochim Biophys Acta 2012; 1825: 29-36. [ Links ]

    72. Iruela-Arispe ML, Carpizo D, Luque A. ADAMTS1: a matrix metalloprotease with angioinhibitory properties. Ann N Y Acad Sci 2003; 995: 183-90. [ Links ]

    73. Remacle AG, Golubkov VS, Shiryaev SA, et al. Novel MT1-MMP small-molecule inhibitors based on insights into hemopexin domain function in tumor growth. Cancer Res 2012; 72: 2339-49. [ Links ]

    74. van Wijngaarden J, Snoeks TJ, van Beek E, et al. An in vitro model that can distinguish between effects on angiogenesis and on established vasculature: actions of TNP-470, marimastat and the tubulin-binding agent Ang-510. Biochem Biophys Res Commun 2010; 391: 1161-5. [ Links ]

    75. Hwang YP, Yun HJ, Choi JH, et al. Suppression of EGF-induced tumor cell migration and matrix metalloproteinase- 9 expression by capsaicin via the inhibition of EGFR-mediated FAK/Akt, PKC/Raf/ERK, p38 MAPK, and AP-1 signaling. Mol Nutr Food Res 2011; 55: 594-605. [ Links ]

    1. Kilfoy BA, Zheng T, Holford TR, et al. International patterns and trends in thyroid cancer incidence, 1973-2002. Cancer Causes Control 2009; 20: 525-31. [ Links ]

    2. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006; 295: 2164-7. [ Links ]

    3. Enewold L, Zhu K, Ron E, et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiol Biomarkers Prev 2009; 18: 784-91. [ Links ]

    4. Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer 2009; 115: 3801-7. [ Links ]

    5. Gursoy A. Rising thyroid cancer incidence in the world might be related to insulin resistance. Med Hypotheses 2010; 74: 35-6. [ Links ]

    6. Rezzonico J, Rezzonico M, Pusiol E, Pitoia F, Niepomniszcze H. Introducing the thyroid gland as another victim of the insulin resistance syndrome. Thyroid 2008; 18: 461-4. [ Links ]

    7. Rezzonico JN, Rezzonico M, Pusiol E, Pitoia F, Niepomniszcze H. Increased prevalence of insulin resistance in patients with differentiated thyroid carcinoma. Metab Syndr Relat Disord 2009; 7: 375-80. [ Links ]

    8. Duran AO, Anil C, Gursoy A, Nar A, Altundag O, Tutuncu NB. The relationship between glucose metabolism disorders and malignant thyroid disease. Int J Clin Oncol. 2012; Jun 30 [Epub ahead of print]. [ Links ]

    9. Wakeford R. The cancer epidemiology of radiation. Oncogene 2004; 23: 6404-28 [ Links ]

    10. Cardis E, Kesminierne A, Ivanov V, et al. Risk of thyroid cancer after exposure to 131-I in childhood. J Natl Cancer Inst 2005; 97: 724-32. [ Links ]

    11. Naing S, Collins B, Schneider A. Clinical behavior of radiation- induced thyroid cancer: factors related to recurrence. Thyroid 2009; 19: 479-85. [ Links ]

    12. American Cancer Society: Cancer Facts and Figures 2012. Atlanta, Ga: American Cancer Society, 2012. [ Links ]

    13. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1167-214. [ Links ]

    14. Pitoia F, Ward L, Wohllk N, et al. Recommendations of the Latin American Thyroid Society on diagnosis and management of differentiated thyroid cancer. Arq Bras Endocrinol Metabol 2009; 53: 884-7. [ Links ]

    15. Pacini F, Schlumberger M, Dralle H, et al. European Thyroid Cancer Taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006; 154: 787-803. [ Links ]

    16. World Health Organization. International Agency for Research on Cancer (IARC) Globocan. En http://globocan.iarc.fr/factsheets/populations/factsheet.aspuno=32#BOTH. Argentina; consultado el 15/9/2012. [ Links ]

    17. Faure E, Soutelo J, Faraj G, Lutfi R, Juvenal G. Estimación de la Incidencia de Cáncer de Tiroides en Capital Federal y el Gran Buenos Aires (período 2003-2011). Rev Argent Endocrinol Metab 2012; 49: 20-4. [ Links ]

    18. Ercolano MA; Gauna A Mortalidad por cáncer de tiroides en Argentina. Período: 2005-2009. Rev Argent Endocrinol Metab 2011; 48 (supl): 71. [ Links ]

    19. Oertel J, Klinck G . Structural changes in the thyroid glands of healthy young men. Med Ann D C 1965; 34: 75-7. [ Links ]

    20. Kovacs G, Gonga G, Vadasz G, et al. Epidemiology of thyroid microcarcinoma found in autopsy series conducted in areas of different iodine intake. Thyroid 2005; 15: 152-7. [ Links ]

    21. Mortensen J, Woolner L, Bennett W . Gross and microscopic findings in clinically normal thyroid glands. J Clin Endocrinol Metab 1955; 15: 1270-80. [ Links ]

    22. Furmanchuk A, Roussak N, Ruchti C .Occult thyroid carcinomas in the region of Minsk, Belarus. An autopsy study of 215 patients. Histopathology 1993; 23: 319-25. [ Links ]

    23. Harach H, Franssila K, Wasenius V. Occult papillary carcinoma of the thyroid: a "normal" finding in Finland. A systematic autopsy study. Cancer 1985; 56: 531-38. [ Links ]

    24. Ottino A, Pianzola, H, Castelletto R.Occult papillary thyroid carcinoma at autopsy in La Plata, Argentina. Cancer 1989; 64: 547-51. [ Links ]

    25. Bosetti C, Bertuccio P, Levi F, Lucchini, F. Negri E, La Vecchia C. Cancer mortality in the European Union, 1970-2003, with a joinpoint analysis. Ann Oncol 2008; 19: 631-40. [ Links ]

    26. AJCC: Thyroid. In: Edge S, Byrd D, Compton C, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, 87-96. [ Links ]

    27. Shah J, Loree T, Dharker D, Strong E .Lobectomy versus total thyroidectomy for differentiated carcinoma of the thyroid: a matched-pair analysis. Am J Surg 1993; 166: 331-5. [ Links ]

    28. Hay I, Grant C, Taylor W, McConahey W. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery 1987; 102: 1088-95. [ Links ]

    29. Sanders L, Cady B. Differentiated thyroid cancer: reexamination of risk groups and outcome of treatment. Arch Surg 1998; 133: 419-25. [ Links ]

    30. Appetecchia M, Scarcello G, Pucci E, Procaccini A. Outcome after treatment of papillary thyroid microcarcinoma. J Exp Clin Cancer Res 2002; 21: 159-64. [ Links ]

    31. Nixon I, Ganly I, Snehal G, et al Thyroid Lobectomy for treatment of well differentiated intrathyroid malignancy. Surgery 2012; 151: 571-9 [ Links ]

    32. Loh KC, Greenspan FS, Gee L, Miller TR, Yeo PP. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. J Clin Endocrinol Metab 1997; 82: 3553-62. [ Links ]

    33. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97: 418-28. [ Links ]

    34. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS, et al. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg 2007; 246: 375-81. [ Links ]

    35. Pitoia F, Ward L Differences Between Latin American and American Associations Thyroid Cancer Guidelines. Thyroid 2010; 20: 361-2. [ Links ]

    36. Russell W, Ibañez M,Clark R et al. Thyroid carcinoma. Classification, intraglandular dissemination, and clinico-pathological study based upon whole organ sections of 80 glands. Cancer 1963; 16: 1425-60. [ Links ]

    37. Katoh R, Sasaki J, Kurihara H, et al. Multiple thyroid involvement intraglandular metástasis in papillary thyroid carcinoma. A clinicopathologic study of 105 consecutive patients. Cancer 1992; 70: 1585-90. [ Links ]

    38. Byrd K, Yawn R, Wilhoit C, et al. Differentiated Thyroid Carcinoma: Current Treatment. Curr Treat Options Oncol 2012; 13: 47-57. [ Links ]

    39. Ito Y, Tomoda C, Uruno T, et al. Clinical significance of metastasis to the central compartment from papillary microcarcinoma of the thyroid. World J Surg 2006; 30: 91-9. [ Links ]

    40. Sato N, Oyamatsuda M, Koyama Y, Emura I, Tamiya Y, Hatakeyama K. Do the level of nodal disease according to the TNM classification and the number of involved cervical nodes reflect prognosis in patients with differentiated carcinoma of the thyroid gland? J Surg Oncol 1998; 69: 151-5. [ Links ]

    41. Grebe SK, Hay ID. Thyroid cancer nodal metastases: biologic significance and therapeutic considerations. Surg Oncol Clin N Am 1996; 5: 43-63. [ Links ]

    42. Machens A, Hinze R, Thomusch O, Dralle H. Pattern of nodal metastasis for primary and reoperative thyroid cancer. World J Surg 2002; 26: 22-28. [ Links ]

    43. Tuttle RM, Rondeau G, Lee NY. A risk-adapted approach to the use of radioactive iodine and external beam radiation in the treatment of well-differentiated thyroid cancer. Cancer Control 2011; 18: 89-95. [ Links ]

    44. Tuttle RM, Tala H, Shah J, et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 2010; 20: 1341-9. [ Links ]

    45. Vaisman F, Shaha A, Fish S, Tuttle R. Initial therapy with either thyroid lobectomy or total thyroidectomy without radioactive iodine remnant ablation is associated with very low rates of structural disease recurrence in properly selected patients with differentiated thyroid cancer. Clin Endocrinol (Oxf) 2011; 75: 112-19. [ Links ]

    46. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med 1998; 338: 297-306. [ Links ]

    47. Mazzaferri EL. An overview of the management of papillary and follicular thyroid carcinoma. Thyroid 1999; 9: 421-27. [ Links ]

    48. Samaan NA, Schultz PN, Hickey RC, Goepfert H, Haynie TP, Johnson DA, et al. The results of various modalities of treatment of well differentiated thyroid carcinomas: A retrospective review of 1599 patients. J Clin Endocrinol Metab 1992; 75: 714-20. [ Links ]

    49. Jonklaas J, Sarlis NJ, Litofsky D, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 2006; 16: 1229-42. [ Links ]

    50. Hay ID, Thompson GB, Grant CS, et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg 2002; 26: 879-85. [ Links ]

    51. Alexander C, Bader JB, Schaefer A, Finke C, Kirsch CM. Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma. J Nucl Med 1998; 39: 1551-4. [ Links ]

    52. Van Nostrand D, Neutze J, Atkins F. Side effects of "rational dose" iodine-131 therapy for metastatic well-differentiated thyroid carcinoma. J Nucl Med 1986; 27: 1519-27. [ Links ]

    53. Van Nostrand D. Sialoadenitis secondary to 131I therapy for well-differentiated thyroid cancer. Oral Dis 2011; 17: 154-61. [ Links ]

    54. Iyer NG, Morris LG, Tuttle RM, Shaha AR, Ganly I. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer 2011; 117: 4439-46. [ Links ]

    55. Brown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve DC, Tward JD. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab 2008; 93: 504-15. [ Links ]

    56. Sawka AM, Thabane L, Parlea L, et al. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid 2009; 19: 451-7. [ Links ]

    57. Podnos YD, Smith DD, Wagman LD, Ellenhorn JD. Survival in patients with papillary thyroid cancer is not affected by the use of radioactive isotope. J Surg Oncol 2007; 96: 3-7. [ Links ]

    58. Pelizzo MR, Boschin IM, Toniato A, et al. Papillary thyroid microcarcinoma (PTMC): prognostic factors, management and outcome in 403 patients. Eur J Surg Oncol 2006; 32: 1144-8. [ Links ]

    59 DeGroot LJ, Kaplan EL, McCormick M, Straus FH. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 1990; 71: 414-24. [ Links ]

    60. Tsang RW, Brierley JD, Simpson WJ, Panzarella T, Gospodarowicz MK, Sutcliffe SB. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. Cancer 1998; 82: 375-88. [ Links ]

    61. Sacks W, Fung CH, Chang JT, Waxman A, Braunstein GD. The effectiveness of radioactive iodine for treatment of low-risk thyroid cancer: a systematic analysis of the peer-reviewed literature from 1966 to April 2008. Thyroid 2010; 20: 1235-45. [ Links ]

    62. Lo CY, Chan WF, Lam KY, Wan KY Optimizing the treatment of AMES high-risk papillary thyroid carcinoma. World J Surg 2004; 28: 1103-9. [ Links ]

    63. Mazzaferri EL, Kloos RT. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001; 86: 1447-63. [ Links ]

    64. DeGroot LJ, Kaplan EL, Shukla MS, Salti G, Straus FH. Morbidity and mortality in follicular thyroid cancer. J Clin Endocrinol Metab 1995; 80: 2946-53. [ Links ]

    65. Martins RG, Caplan RH, Lambert PJ, Rooney B, Kisken WA. Management of thyroid cancer of follicular cell origin: Gundersen/Lutheran Medical Center. J Am Coll Surg 1997; 185: 388-97. [ Links ]

    66. Herrera MF, López-Graniel CM, Saldaña J, et al. Papillary thyroid carcinoma in Mexican patients: clinical aspects and prognostic factors. World J Surg 1996; 20: 94-9. [ Links ]

    67. Palme CE, Waseem Z, Raza SN, Eski S, Walfish P, Freeman JL. Management and outcome of recurrent well-differentiated thyroid carcinoma. Arch Otolaryngol Head Neck Surg 2004; 130: 819-24. [ Links ]

    68. Sawka AM, Brierley JD, Tsang RW, et al. An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer. Endocrinol Metab Clin North Am 2008; 37: 457-80. [ Links ]

    69. Robbins RJ, Tuttle RM, Sonenberg M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin. Thyroid 2001; 11: 865-9. [ Links ]

    70. Robbins RJ, Larson SM, Sinha N, et al. A retrospective review of the effectiveness of recombinant human TSH as preparation for radioiodine thyroid remnant ablation (brief communication). J Nucl Med 2002; 43: 1482-8. [ Links ]

    71. Pacini F, Molinaro E, Castagna MG, et al. Ablation of thyroid residues with 30 mCi 131I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab 2002; 87: 4063-8. [ Links ]

    72. Pitoia F, Degrossi OJ, Niepomniszcze H. Why should the radioiodine dose be different in patients with differentiated thyroid carcinoma prepared with recombinant human TSH? Eur J Nucl Med Mol Imaging 2004; 31: 924; author reply: 924-5. [ Links ]

    73. Barbaro D, Boni G, Meucci G, et al. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation. J Clin Endocrinol Metab 2003; 88: 4110-5. [ Links ]

    74. Pacini F, Ladenson PW, Schlumberger M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 2006; 91: 926-32. [ Links ]

    75. Pitoia F, El Tamer E, Schere DB, Passerieu M, Bruno OD, Niepomniszcze H. Usefulness of recombinant human TSH aided radioiodine doses administered in patients with differentiated thyroid carcinoma. Medicina (B Aires) 2006; 66: 125-30. [ Links ]

    76. Pilli T, Brianzoni E, Capoccetti F, et al. A comparison of 1850 MBq (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant TSH-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J Clin Endocrinol Metab 2007; 92: 3542-6. [ Links ]

    77. Chianelli M, Todino V, Graziano FM, et al. Low-activity (2.0 GBq; 54 mCi) radioiodine post-surgical remnant ablation in thyroid cancer: comparison between hormone withdrawal and use of rhTSH in low-risk patients. Eur J Endocrinol 2009; 160: 431-6. [ Links ]

    78. Pitoia F, El Tamer E, Salvai ME, Niepomniszcze H. Protocol for thyroid remnant ablation after recombinant TSH in thyroid carcinoma. Medicina (B Aires) 2009; 69: 148-52. [ Links ]

    79. Hnscheid H, Lassmann M, Luster M, et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med 2006; 47: 648-54. [ Links ]

    80. Rosário PW, Borges MA, Purisch S. Preparation with recombinant human thyroid-stimulating hormone for thyroid remnant ablation with 131I is associated with lowered radiotoxicity. J Nucl Med 2008; 49: 1776-82. [ Links ]

    81. Mallick U, Harmer C, Yap B, et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med 2012; 366: 1674-85. [ Links ]

    82. Schlumberger M, Catargi B, Borget I et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med 2012; 366: 1663-73. [ Links ]

    83. Alexander EK, Larsen PR. Radioiodine for thyroid canceris less more? N Engl J Med 2012; 366: 1732-3. [ Links ]

    1. Cetrángolo A, Dubra F, Kantor IN. Tuberculosis pulmonar producida por micobacteria aviaria. An Cat Pat Clin Tub 1967; 26: 117-9. [ Links ]

    2. Dirac MA, Horan KL, Doody DR, et al. Environment or Host?: A case-control study of risk factors for Mycobacterium avium Complex lung disease. Am J Respir Crit Care Med 2012; Aug 2 [Epub ahead of print]. [ Links ]

    3. WHO/ FAO. Codex Alimentarius. Milk and Milk Products. Second Ed. Rome: Food and Agriculture Organization, 2011. En: ftp://ftp.fao.org/codex/Publications/Booklets/Milk/Milk_2011_EN.pdf ; consultado el 12/6/2012. [ Links ]

    4. Perez AM, Ward MP, Ritacco V. Simulation-model evaluation of bovine tuberculosis-eradication strategies in Argentine dairy herds. Prev Vet Med 2002; 54: 351-60. [ Links ]

    5. de Kantor IN, Paolicchi F, Bernardelli A, et al. Bovine tuberculosis in Latin American countries. Current situation and recommendations. Workshop sponsored by OIE, 3rd Latin American Congress on Zoonoses. Buenos Aires, Argentina, June 19, 2008. En: http://www.rr-americas.oie.int/in/proyectos/zoonosis/in_tuberculosis_recomendaciones_ago.html; consultado el 1/7/2012. [ Links ]

    6. Pérez AM, Ward MP, Ritacco V. Modelling the feasibility of bovine tuberculosis eradication in Argentina. Revue scient tech Off intern Epizooties 2011; 30: 635-43 [ Links ]

    7. WHO.Global Tuberculosis Control. WHO Report 2012. Annex 4, Global, regional and country specific data for key indicators. Geneva: WHO, 2012. En: http://www.who.int/tb/publications/global_report/gtbr12_annex4.pdf; consultado el 27/10/2012. [ Links ]

    8. ANLIS (Administración Nacional de Laboratorios e Institutos de Salud). Notificación de casos de tuberculosis en la R. Argentina. En: http://www.redbioquimicasf.com.ar/redes/tuberculosis/2011_notificacion_tb_2010.pdf; consultado el 15/9/2012. [ Links ]

    9. Organización Panamericana de la Salud (OPS/OMS). Estructura y organización de las redes de laboratorios de tuberculosis en Latinoamérica. Encuesta de Laboratorios de Tuberculosis realizada por el Programa Regional de Tuberculosis de OPS/OMS. En: http://www2.paho.org/hq/dmdocuments/2010/resultados_encuesta_TB.pdf; consultado el 12/9/2012. [ Links ]

    10. Ritacco V, Sequeira MD, de Kantor IN. Human tuberculosis caused by Mycobacterium bovis in Latin America and the Carribbean. En: Chapter 3, Mycobacterium bovis infection in animals and humans (C.O.Thoen, J.H. Steele & M.J. Gilsdorf eds), 2nd edition, Ames, IA: Blackwell Ed, 2006, p 13-17. [ Links ]

    11. de Kantor IN, Ambroggi M, Poggi S, et al. Human Mycobacterium bovis infection in ten Latin American countries. Tuberculosis 2008; 88: 358-65. [ Links ]

    12. Di Lonardo M, Isola NC, Ambroggi M, et al. Mycobacteria in HIV-infected patients in Buenos Aires. Tubercle and Lung Disease 1995; 76: 185-9. [ Links ]

    13. Córdova E, Gonzalo X, Boschi A, et al. Human Mycobacterium bovis infection in Buenos Aires: epidemiology, microbiology and clinical presentation. Int J Tuberc Lung Dis 2012; 16: 415-7. [ Links ]

    14. Hlavsa MC, Moonan PK, Cowan LS, et al. Human tuberculosis due to Mycobacterium bovis in the United States, 1995-2005. Clin Infect Dis 2008; 47: 168-75. [ Links ]

    15. de Kantor IN, LoBue PA, Thoen CO. Human tuberculosis caused by Mycobacterium bovis in the United States, Latin America and the Caribbean. Int J Tuberc Lung Dis 2010; 14:1369-73. [ Links ]

    16. Rodwell TC, Moore M, Moser KS, Brodine SK, Strathdee SA. Tuberculosis from Mycobacterium bovis in binational communities, United States. Emerg Infect Dis 2008; 14: 909-16 [ Links ]

    17. Park D, Qin H, Jain S, et al. Tuberculosis due to Mycobacterium bovis in patients coinfected with Human Immunodeficiency Virus. Clin Infect Dis 2010; 51:1343-6. [ Links ]

    18. United States Department of Agriculture (USDA/APHIS). Bovine Tuberculosis Disease Information. En: http://www.aphis.usda.gov/animal_health/animal_diseases/tuberculosis/ ; consultado el 15/9/2012. [ Links ]

    19. Mandal S, Bradshaw L, Anderson LF. Investigating transmission of Mycobacterium bovis in the United Kingdom in 2005 to 2008. J Clin Microbiol 2011;49: 1943-50. [ Links ]

    20. Ojo O, Sheehan S, Corcoran GD, et al. Mycobacterium bovis strains causing smear-positive human tuberculosis, Southwest Ireland. Emerg Infect Dis 2008; 14: 1931-4. [ Links ]

    21. European Commision Veterinary and International Affaires. Report of the Bovine Tuberculosis Sub Group, SSANCO/2012/11191.Bovine tuberculosis statistics and costs. En: http://www.bovinetb.info/ ;consultado el 19/9/2012 [ Links ]

    22. The Bovine TB Open Forum. Regular bovine TB outbreaks in the UK and overseas, 2010. BovineTB.co.uk. En: http://www.bovinetb.co.uk/forum_topic.php?thread_id=26 ;consultado el 12/9/2012. [ Links ]

    23. Majoor CJ, Magis-Escurra C, van Ingen J, Boeree MJ, van Soolingen D. Epidemiology of Mycobacterium bovis disease in humans, The Netherlands, 1993-2007. Emerg Infect Dis 2011;17:457-63. [ Links ]

    24. Kolditz M, Koschel D, Philipp E, Hffken G. Retrospective analysis of tuberculosis caused by Mycobacterium bovis 2004-2008. Pneumologie 2010;64: 675-8. [ Links ]

    25. Delaune D, Janvier F, Rapp C, et al. Update on Mycobacterium bovis infections in France: 4 cases reports. Ann Biol Clin (Paris) 2012;70: 231-6. [ Links ]

    26. Ingram PR, Bremner P, Inglis TJ, Murray RJ, Cousins DV. Zoonotic tuberculosis: on the decline. Commun Dis Intell 2010;34:339-41. [ Links ]

    27. Rodríguez E, Sánchez LP, Pérez S, et al. Human tuberculosis due to Mycobacterium bovis and M. caprae in Spain, 2004-2007. Int J Tuberc Lung Dis 2009;13: 1536-41. [ Links ]

    28. Portillo-Gómez EG, Sosa-Iglesias I. Molecular identification of Mycobacterium bovis and the importance of zoonotic tuberculosis in Mexican patients. Int J Tuberc Lung Dis 2011;15: 1409-14. [ Links ]

    29. Sobral LF, Duarte RS , Vieira GB, Silva MG, Boechat N, Fonseca Lde S. Identification of Mycobacterium bovis among mycobacterial isolates from human clinical specimens at a university hospital in Rio de Janeiro, Brazil. J Bras Pneumol 2011;37: 664-8. [ Links ]

    30. Rocha A, Elias AR, Sobral LF, et al. Genotyping did not evidence any contribution of Mycobacterium bovis to human tuberculosis in Brazil. Tuberculosis 2011;91: 14-21. [ Links ]

    31. Rivas C, Greif G, Coitinho C, Araújo L, Laserra P, Robello C. Primeros casos de tuberculosis pulmonar por Mycobacterium bovis. Una zoonosis reemergente en Uruguay. Rev Med Urug 2012 (en prensa). [ Links ]

    32. Garín A. Programa de Control/Erradicación de tuberculosis bovina en Uruguay, DIEA. Ministerio de Ganadería, Agricultura y Pesca. Anuario Estadístico Agropecuario 2011. República Oriental del Uruguay. En: http://www.mgap.gub.uy/Dieaanterior/Anuario2011/DIEA-Anuario-2011-web.pdf; consultado el 12/6/2012. [ Links ]

    33. Bicca da Silveira G. Atualizações do PNCEBT. Brasília, DF, 2012. En: http://www.agricultura.gov.br; consultado el 23/8/2012. [ Links ]

    34. Maxa V, Paredes L, Rivera A, Ternicier C. National control and eradication program of bovine tuberculosis in Chile. Veterinary Microbiology 2011; 151: 188-91. [ Links ]

    35. Evans JT, Smith EG, Banerjee A, et al. Cluster of human tuberculosis caused by Mycobacterium bovis: evidence for person- to- person transmission in the UK. The Lancet 2007; 369: 1270-6. [ Links ]

    36. Godreuil S, Jeziorski E, Bañuls AL, Fraisse T, Van de Perre P, Boschiroli ML. Intrafamilial cluster of pulmonary tuberculosis due to Mycobacterium bovis of the African 1 clonal complex. J Clin Microbiol 2010; 48: 4680-3. [ Links ]

    37. Etchechoury I, Valencia GE, Morcillo N, et al. Molecular typing of Mycobacterium bovis isolates in Argentina: first description of a person-to-person transmission case. Zoonoses Public Health 2010;57: 375-81. [ Links ]

    38. Blázquez J, Espinosa de Los Monteros LE, Samper S, et al. Genetic characterization of multidrug-resistant Mycobacterium bovis strains from a hospital outbreak involving human immunodeficiency virus-positive patients. J Clin Microbiol 1997; 35: 1390-3. [ Links ]

    39. Rivero A, Márquez M, Santos J, et al. High rate of tuberculosis reinfection during a nosocomial outbreak of multidrug-resistant tuberculosis caused by Mycobacterium bovis strain B. Clinical Infectious Diseases 2001;32: 159-61. [ Links ]

    40. González C, Sáenz C, Herrmann E, Jajati M, Kaplán P, Monzón D. Tratamiento directamente observado de la tuberculosis en un hospital de la ciudad de Buenos Aires. Medicina (B Aires) 2012; 72: 371-9. [ Links ]

    41. Smith I. Qué es DOTS?. En: http://www.paho.org/spanish/dd/pub/Tuberculosis-55.pdf; consultado el 15/9/2012. [ Links ]

    2. McKusick V. Hyperostosis frontalis interna. Alternative titles; symbols. MORGAGNI-STEWART-MOREL SYNDROME. En: www.omim.org/entry/144800; consultado el 17-8-2012. [ Links ]

    3. Morgagni GB: The seat and causes of diseases investigated by anatomy. Traducción inglesa de De sedibus et causis morborum per anatomem indagatis (1761) de Benjamin Alexander. London: Millar, 1769. Book II, Letter XXVII, Article 2. p 832-5. [ Links ]

    4. Morgagni GB. Adversaria anatomica sexta. Leyden: Langerak, 1740. Animadversio LXXXIV, p 109-10. En: http://books.google.com.ar; consultado el 20-8-2012. [ Links ]

    5. Stewart RM. Localized cranial hyperostosis in insane. J Neurol Psycopath 1928, 8: 321. [ Links ]

    6. Perkins OC, Biglan AM. Hyperostosis frontalis interna. Review of the literature. Psychiatr Q 1938; 12: 341-50. [ Links ]

    7. Bassetti CL. Swiss neurological eponyms. Schweiz Arch Neurol Psychiatr 2008: 159: 232-46. (Morel p 244). [ Links ]

    8. Morel F. L'hyperostose frontale interne. Syndrome de l'hyperostose frontale interne avec adipose et troubles cérébraux. Paris: Doin, 1930 (citado por 6 y 7). [ Links ]

    9. Hershkovitz I, Greewald C, Rothschild BM, et al. Hyperostosis Frontalis Interna: An Anthropological Perspective. Am J Physic Anthrop 1999; 109: 303-25. [ Links ]

    10. Raikos A, Paraskevas GF, Yusuf F, et al. Ethiopathogenesis of hyperostosis frontalis interna: A mystery still. Ann Anat 2011: 193: 453-8. [ Links ]

    11. May H, Peled N, Gali D, Janan A, Hershkovitz I. Hyperostosis Frontalis Interna: What Does it Tell Us About our Health? Am J Human Biol 2011; 23: 392-7. [ Links ]

    12. Flohr S, Witzel C. Hyperostosis frontalis interna. A marker of social status? Evidence from the Bronze- Age "high society" of Qatna, Syria. Homo 2011; 62: 30-43. [ Links ]

    1. Mukherjee S. El emperador de todos los males. Una biografía del cáncer. Buenos Aires: Taurus, 2010, 706 pp. [ Links ]

    2. Pasqualini CD, Ruggiero RA, Bustuoabad OD, Nepomnaschy I, Piazzon I. Experimental onco-immunology revisited. CCTR (Current Cancer Therapy Reviews) 2005; 1: 289-98. [ Links ]

    3. Pasqualini CD, Acevedo S. Investigación en cáncer y citogenética. Buenos Aires: EUDEBA, Ciencia Joven, 2007, 100 pp. [ Links ]

    4. Pasqualini CD. Etiología del cáncer: del ratón al hombre. Medicina (B Aires) 1985; 45: 65-76. [ Links ]

    5. Pasqualini CD. La etiología del cáncer. Vigencia de cinco paradigmas sucesivos. Medicina (B Aires) 2003; 63: 757-60. [ Links ]

    6. Harris H. Standing on Boveri's Shoulders. J Cell Sci 2008; 121: 3. doi: 10.1242/jcs.017483. [ Links ]

    7. Boveri T. Concerning the Origin of Malignant Tumours. Translated and annotated by Henry Harris. J Cell Sci 2008; 121: (Suppl.1):1-84; doi:10.1242/jcs.025742. [ Links ]

    8 Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nature Med 2004; 10: 789-99. [ Links ]

    9. Bishop JM. Cancer: the rise of the genetic paradigm. Genes Develop 1995; 9: 1309-15. [ Links ]

    10. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow. Lancet 2001: 357: 539-45. [ Links ]

    11. Pasqualini CD. Papel bivalente del sistema inmune en el crecimiento tumoral. Medicina (B Aires) 2004; 64: 277-80. [ Links ]

    12. Filippa DA, Pasqualini CD. Morphological study of allogeneic tumor growth in mice bearing a glass cylinder. Medicina (B Aires) 1975; 35: 29-36. [ Links ]

    13. Pasqualini CD. La guerra contra el cáncer. Medicina (B Aires) 2011; 71: 496-99. [ Links ]

    14. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity´s roles in cancer suppression and promotion. Science 2011; 331: 1565-70. [ Links ]

    15. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Science 2011; 144: 646-54. [ Links ]

    1. Waddington CH. The strategy of the genes; a discussion of some aspects of theoretical biology. London: Allen& Unwin, 1957. [ Links ]

    2. King TJ, Briggs R. Changes in the nuclei of differentiating gastrula cells, as demonstrated by nuclear transplantation. Proc Natl Acad Sci USA 1955; 41: 321-5. [ Links ]

    3. Gurdon JB. The developmental capacity of nuclei taken from intestinal epithelium cells of feeding tadpoles. Journal of Embryology and Experimental Morphology 1962; 10: 622-40. [ Links ]

    4. Wilmut I, Schnieke AE, McWhir J, Kind AJ, Campbell KHS. Viable offspring derived from fetal and adult mammalian cells. Nature 1997; 385: 810-3 [ Links ]

    5. Jaim Etcheverry G. Premio Nobel en Fisiología o Medicina 2007: Diseñando genomas de ratón. Medicina (B Aires) 2008; 68: 93-6. [ Links ]

    6. Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science 1998; 282: 1145-7. [ Links ]

    7. Bardin J. Was anyone snubbed in Monday's Nobel Prize announcement? Los Angeles Times. October 8, 2012 [ Links ]

    8. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663-76. [ Links ]

    9. Pasqualini CD. Reprogramación de fibroblastos humanos a células madre pluripotentes. Nuevo paradigma en medicina regenerativa. Medicina (B Aires) 2008; 68: 181-3. [ Links ]

    10. Semeniuk G. Células madre. Vida más allá de la muerte. Medicina (B Aires) 2012; 72: 43-4. [ Links ]

    11. Gurdon J. Nuclear reprogramming in eggs. Nature Medicine 2009; 15: vii-x. [ Links ]

    12. Yamanaka S. Ekiden to iPS cells. Nature Medicine 2009; 15: xi-xiv. [ Links ]